<DOC>
	<DOCNO>NCT02618109</DOCNO>
	<brief_summary>B-acute lymphoblastic leukaemia ( ALL ) common childhood malignancy . Despite enhancement childhood B-ALL outcome , relapse remain difficult treat . Several study adult acute myeloid leukaemia show proliferation immunosuppressive cell -particularly T regulatory ( Treg ) cell deficient natural killer ( NK ) cells- associate poor response chemotherapy . However , study do childhood ALL none relapse B-ALL . Moreover , newly describe immunosuppressive B cell subset ( Breg cell ) seem role oncogenesis mouse model , significance never evaluate human cancer . The purpose study prospectively evaluate immune status child newly diagnose first relapse B-cell ALL , compare result child treat B-ALL complete remission . Classic lymphocytic phenotype , proportion immunosuppressive cell ( Treg cell , deficient NK cell , Cytotoxic T-lymphocyte-associated protein 4 and/or Programmed T cell death 1 ) thymopoiesis evaluate . The investigator assume increase immunosuppressive cell proportion could associate B-ALL relapse .</brief_summary>
	<brief_title>Identification New Immune Factors Specific Relapse Childhood B Lineage Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Immunologic Factors</mesh_term>
	<criteria>1 . Inclusion Criteria relapse Group : Children age 1 18 year time first BALL relapse diagnosis Obtention oral write consent parent Parents affiliate social security system 2 . Inclusion Criteria control Group : Children age 1 18 year enrol FRALLE EORTC treatment protocol , treat BALL complete molecular remission Obtention oral write consent parent Parents affiliate social security system 3 . Exclusion criterion control Group relapse Group : Children hematologic syndrome predispose hematologic neoplasia ( Fanconi 's anaemia , Diamond Blackfan anaemia â€¦ ) acute leukemia secondary previous treatment , allogenic hematopoietic stem cell transplantation relapse</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>B acute lymphoblastic leukemia</keyword>
	<keyword>leukemia relapse</keyword>
	<keyword>pediatric onco-hematology</keyword>
</DOC>